cyrilzakka/clinical-trials huggingface dataset:
Systematic Screening for Obstructive Sleep Apnea During Preoperative Consultation Using AI-preoperative Agents

The goal of this observational study is to evaluate the feasibility of a systematic screening protocol for Obstructive Sleep Apnea (OSA) during preoperative anesthesia consultations in adults aged 50 and older undergoing elective surgery. The main questions it aims to answer are:

* Does the systematic screening protocol increase the proportion of patients identified as being at high risk for OSA compared to standard care?
* What is the impact of systematic screening on postoperative outcomes, including complications, length of stay, and mortality?

Researchers will compare standard care practices (before implementation) to the systematic screening protocol (after implementation) to determine the effect on OSA detection rates and clinical outcomes.

Participants will:

* Complete the STOP-BANG questionnaire during their anesthesia consultation.
* (Optional) Have a facial photograph taken to analyze morphometric characteristics that may correlate with OSA risk.
* Be referred for further diagnostic testing if identified as high-risk for OSA.


Eligibility Criteria:
Inclusion Criteria:

* All patients with a national health identifier affiliated with the social security system, aged over 18, including French individuals over 50 years old, in scheduled anesthesia consultation with STOP BANG \> 5 or \> 4 with BMI \> 35

Exclusion Criteria:

* Refusal to participate in the study, age under 50, not affiliated with the social security system, minor or under legal protection
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study will assess the real-world effectiveness of upadacitinib on early and sustained response along adolescent and adult participants with AD. This study also aims to understand upadacitinib utilization patterns in real-world clinical practice.

Upadacitinib (RINVOQ) is approved in the EU for the treatment of moderate to severe AD in adults and adolescents 12 years and older who are candidates for systemic therapy. Approximately 772 adolescent and adult participants with AD will be enrolled at up to 200 sites in Germany.

Participants will receive oral upadacitinib tablets as prescribed by the physician prior to enrolling in this study in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population, and indication. The overall duration of the study is approximately 2 years.

Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.


Eligibility Criteria:
Inclusion Criteria:

* Body weight \>=30 kg at baseline for participants between \>=12 and \<18 years of age.
* Physician confirmed diagnosis of moderate to severe atopic dermatitis at the time of enrollment.
* Upadacitinib initiated as per the local label. The decision to prescribe upadacitinib must have been made prior to and independently of study participation.
* Medical and medication history available at least for the last 6 months.

Exclusion Criteria:

- Current participation in interventional research (note: this does not include non-interventional, post-marketing observational studies, or registry participation).
Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma

This study is divided into three stages. In the first stage, the investigators try to explore the objective clinical imaging standard of cN0PTC on the basis of previous studies, formulate the "clinical imaging standard of cN0PTC", and randomly enroll 2000 patients under the premise of meeting the standard to establish the "predictive model of cN0-pN+PTC".

In the second stage, 2000 patients will be enrolled to test and improve the evaluation efficiency of "cN0-pN+PTC prediction model".

In the third stage, 2 000 patients without lymph node metastasis assessed by "cNo-pN+ PTC prediction model" will be randomly divided into experimental group and control group. The experimental group will be treated with pCND, while the experimental group will be treated without pCND. The central lymph node metastasis probability, the number and size of metastatic lymph nodes in the control group will be observed after operation. The two groups will be followed up for 5, 10, 15 and 20 years to observe the RFS and OS, so as to further evaluate the "cN0-pN+PTC prediction model" scientifically.


Eligibility Criteria:
Inclusion Criteria:

* Phase I and II:

  1. aged 18 to 80 years old;
  2. the primary treatment of patients with unilateral or bilateral PTC;
  3. ultrasound showed that the tumor was localized in the thyroid gland, and the maximum diameter of each lesion was less than 4cm;
  4. ultrasonography of cervical VI lymph nodes: the shortest diameter \< 4 mm, no calcification, no cystic change, no local or global echo enhancement;
  5. CT scan of cervical VI lymph nodes: the shortest diameter \< 4 mm, no calcification, no cystic change, no enhancement (CT value 40HU or not higher than banded muscle level), no cluster distribution;
  6. patients will voluntarily enter the study after informed consent;

Phase III:

1. aged from 18 to 80 years old;
2. ultrasound showed that the tumor was localized in the thyroid gland, and the maximum diameter of each lesion was less than 4cm;
3. Unilateral or bilateral PTC without lymph node metastasis assessed by "cNo-pN+ PTC prediction model";
4. patients will voluntarily enter the study after informed consent.

Exclusion Criteria:

* (1) patients refused to participate in the study; (2) non first operation patients; (3) Lateral cervical lymph nodes or distant metastasis; (4) Hashimoto's disease; (5) history of neck trauma.
HR-QoL and Sexuality in Mirena Inserted Contraception Users

The purpose of this study is to evaluate the changes in the quality of life, as well as in the sexual activity, in women inserted with MIRENA, a hormonal contraceptive intra-uterine system, over the first 12 months of use. Patients switching from oral contraception to an intrauterine contraceptive device (here: MIRENA) will be observed in the first year post MIRENA insertion.


Eligibility Criteria:
Inclusion Criteria:

* Healthy woman willing to, or having to switch from her OC to another contraceptive method

Exclusion Criteria:

- Any contraindication to Mirena insertion/use
VIDeOS for Smoking Cessation

The purpose of the current study is to pilot the efficacy, feasibility, and acceptability of an evidence-based smoking cessation intervention adapted for cancer patients and delivered via video. Investigators aim to assess if this intervention is considered acceptable by participants, feasible to implement, and effective at increasing knowledge about smoking cessation before conducting a fully powered clinical trial.

A randomized controlled pilot study is being conducted to test the acceptability and feasibility of a smoking cessation intervention tailored for cancer patients that is delivered via video. Participants will be in a video intervention or control group that receives information about quitting smoking. Participants will complete surveys prior to randomization, and will complete additional surveys one week, one month, and three months post-randomization to provide their thoughts about the videos, information about changes to smoking behaviors, and knowledge about quitting smoking.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* Diagnosed with cancer (any type)
* Receiving care at Medical University of South Carolina
* Reads and understands English language
* Currently smoking cigarettes (any amount)

Exclusion Criteria:

- Unstable or poorly managed medical or psychiatric conditions that impair cognition and ability to provide informed consent (e.g., dementia, active psychosis).
Upper Cross Syndrome Rehabilitation Strengthening of the Dorsal Erector Muscles

The purpose of this study is to determine which treatment is more effective for chronic neck pain associated with Upper Cross Syndrome.

Patients will divided in two groups, control and intervention. Control Group will do exercises of strengthening of Deep Cervical Flexors, Shoulder External Rotators and Adduction of Scapulae.

Intervention group will do the same plus Strengthtening of Erector Thoracic.

Eligibility Criteria:
Inclusion Criteria:

* Chronic neck pain for at least 3 months
* 52º or less in the craniovertebral angle
* 50º or less in the shoulder angle

Exclusion Criteria:

* herniated disk, radiculopathy, diseases of the spine
Clinical Performance of the Automated Closed-loop Minimum Viable Prototype

The goal of this clinical trial is to evaluate a minimum viable prototype for automated closed-loop administration of propofol in deep sedated patients under invasive mechanical ventilation in the ICU. The main question it aims to answer is:

• whether the minimum viable prototype for automated closed-loop administration of propofol is effective in keeping patients in deep sedation using the lowest possible dose of propofol Participants will undergo deep sedation using the minimum viable prototype for automated closed-loop propofol administration.

The usual practice of sedation will be compared with the practice of sedating with the minimum viable prototype to see if the infusion rate of propofol is decreased

The design of the study will consist of each patient being exposed to both forms of administration (matched pair study) during a 12-hour day (8:00 a.m. to 8:00 p.m.) in a randomized manner. Specifically, a patient will be given propofol infusion in open-loop mode in the first 5 hours (8:00 a.m. to 1:00 p.m.) and the next 5 hours in closed-loop mode (3:00 p.m. to 8:00 p.m.) with a wash-out period of 2 hours. The order will be randomly determined for each patient. This design will allow the use of the prototype to be evaluated under highly controlled conditions by a trained operator dedicated exclusively to this function.

Eligibility Criteria:
Inclusion Criteria:

* Indication of deep sedation for more than 48 hours

Exclusion Criteria:

* Dementia
* Cranial surgery
* Hypoxic-ischemic encephalopathy
* Chronic liver damage Child C
* History of substance and drug abuse that can alter EEG recordings or the metabolization of drugs (antipsychotics, cocaine, benzodiazepines, opioids)
* Pregnant women
* allergic to propofol
* EEG sensor of the BIS® Covidien cannot be installed
Comparison of Nasal and Forehead Oximetry in Critically Ill Patients at Risk for Decreased Peripheral Perfusion

Continuous pulse oximetry monitoring is the standard of care in critically ill patients in emergency departments, operating rooms and intensive care units. In patients with poor peripheral perfusion (low blood flow) due to peripheral vascular disease, low body temperature, or shock and the use of medications to raise the blood pressure, clinicians have difficulty obtaining an accurate measurement. This study compares the accuracy of forehead oximetry sensors to nasal alar sensors to lab oximetry measures and on the rate of device related pressure ulcers with both.

Continuous pulse oximetry monitoring is the standard of care in critically ill patients in emergency departments, operating rooms and intensive care units. In patients with poor peripheral perfusion (low blood flow) due to peripheral vascular disease, low body temperature, or shock and the use of medications to raise the blood pressure, clinicians have difficulty obtaining an accurate measurement. Several studies have demonstrated the utility of forehead sensor measurements under these clinical conditions. Forehead sensor measurement is considered to be a more central measurement than with digit or ear sensors. However the sensor requires a head band for accurate measurement. On a regular basis, the forehead sensor has led to pressure ulcer development at Barnes-Jewish Hospital despite following vendor recommendations for alternating placement every 8 hours from one side of the forehead to the other. An alternate sensor placed on the nose has recently demonstrated rapid detection of induced drops in oxygen saturation. It has also demonstrated correlation with arterial oxygen saturation measured in a clinical laboratory. The oxygen saturation measurement from the nose is also considered a central measurement. However, studies of the nose sensor were conducted in healthy subjects or during anesthesia care over several hours. Therefore, research is needed to examine the accuracy of the nose sensor in the ICU patient population. In addition, due to concerns for sensor related pressure ulcers in patients with decreased perfusion, the sensor needs to be evaluated for extended periods of time.

Eligibility Criteria:
Inclusion Criteria:

1. Presence of an existing arterial catheter for blood sampling and one of the following:

1. Difficulty obtaining a consistent signal from a digit or ear sensor or
2. On pressors of at least 0 .10 mcg/kg/min of norepinephrine or
3. Core temperature \< or equal to 35 degrees C

Exclusion Criteria:

1. Anatomic impediments (burns, wounds, dressings, etc.) to placement of the sensor on the forehead or nasal alar
2. History of known dyshemoglobinemias evidenced by carboxyhemoglobin levels \> 10% or methemoglobin level \> 2%
3. Severe anemia with hemoglobin \< 5 g/dL
4. Pregnant women
Evaluating the Efficacy and Feasibility of a Novel Wireless ECG Recording System in Monitoring Patients After Atrial Fibrillation Ablation Procedure

The investigators goal in this study is to examine the feasibility and efficacy of AliveCor iphone case monitoring device in monitoring patients after AF ablation by comparing transmissions using Alive Cor with transmissions from a traditional transtelephonic monitor (TTM).

A secondary goal is to assess the ease of use of AliveCor device compared to traditional TTM system from the patient's perspective


Eligibility Criteria:
Inclusion Criteria:

1. Male or female between \> 18 and \< 75 years of age
2. Paroxysmal or persistent atrial fibrillation
3. Scheduled to undergo an AF ablation procedure
4. Already has iPhone 4 or iPhone 4S with data plan
5. Willing to use the iPhone Alive Cor case
6. Written informed consent

Exclusion Criteria:

1. Unable or unwilling to use the Alive Cor case for their iPhone or iPhone 4S
2. Residing outside the United States
ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Colorectal Cancer Surgery

The study assesses the impact on quality of care of implementing the ERAS (Enhanced Recovery After Surgery) protocol for colorectal cancer surgery in the network of public hospitals in the Regione Piemonte (North-West Italy). Every hospital is a cluster entering the study treating patients according to its current clinical practice. On the basis of a randomized order, each hospital switches from current clinical practice to the adoption of the ERAS protocol.

ERAS (Enhanced Recovery After Surgery) protocol is a multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response following surgery. Even if efficacy and safety of ERAS protocol in colorectal surgery is well-established in the literature, its implementation is limited to few selected centres in Piemonte. The aim of the study is to extend the implementation of the ERAS protocol to whole regional network of hospitals. Specific objectives are to estimate its impact on different dimensions of quality of care, including length of stay, complications and patient satisfaction, and to identify possible barriers or facilitating factors.

Eligibility Criteria:
Inclusion Criteria:

* All the hospital wards within the Piemonte Region performing colorectal cancer surgery
* All the patients receiving an elective surgery for colorectal cancer, with or without protective stoma.

Exclusion Criteria:

* Hospital wards performing less than 30 expected cases per year
* Emergency surgery
* High severity cases not allowing ERAS protocol implementation (i.e. American Society of Anesthesiologists score: ASA V).
Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh

The safety and effectiveness of AmBisome 15 mg/kg, given over 15 days in 5 biweekly infusions of 3 mg/kg on an outpatient basis, is evaluated in clinically diagnosed PKDL patients of 12 years and older in a highly endemic area in Bangladesh. This is a prospective study, with the objective to assess final cure 12 months after treatment.

The safety and effectiveness of AmBisome 15 mg/kg, given over 15 days in 5 biweekly infusions of 3 mg/kg on an outpatient basis, was evaluated in clinically diagnosed PKDL patients of 12 years and older in a highly endemic area in Bangladesh. This was a prospective study, with the objective to assess final cure 12 months after treatment. Clinical response was monitored at 1, 3, 6, and 12 months after treatment, and safety during and up until one month after treatment. A total of 280 patients recruited between 8 April and 25 November 2014 received AmBisome. Of these, 272 were assessed at 12 months.

Eligibility Criteria:
Inclusion Criteria:

-Patients of 12 years and older with probable PKDL (skin lesions strongly suggestive of PKDL with exclusion of other skin diseases, a history of VL treatment and a positive serological rK39 test)

Exclusion Criteria:

* PKDL and concurrent VL
* Prior treatment for PKDL
* On medication with a side effect profile overlapping with that of AmBisome
* A known hypersensitivity to AmBisome
* Pregnant and lactating women,
* Known cardiac disease, hepatic impairment or another severe chronic underlying disease -Renal impairment (baseline serum creatinine \> 1.3 mg/dL)
* Serum potassium \<3.5mmol/L at baseline
Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy

This is a multicenter, open, prospective and randomized study aimed at evaluating the pharmacokinetics of the tablet formulation of lopinavir/r administered in combination with two nucleoside analogs to HIV-infected pregnant women at two different dosages:

* Group 1 (standard dosage): 200/50 mg lopinavir/r, 2 tablets every 12 hours, plus two nucleoside analogs.
* Group 2 (increased dosage): 200/50 mg lopinavir/r, 2 tablets every 12 hours until the end of the second trimester of gestation (24 weeks) and 3 tablets every 12 hours in the third trimester (from 25 weeks on), plus two nucleoside analogs.

Treatment will be initiated at any time between 14 and 30 weeks of gestation and will be maintained for at least 6 weeks after delivery.

The objectives are:

* To compare the pharmacokinetic parameters of the standard and increased dosage of the tablet formulation of lopinavir/r during pregnancy.
* To determine whether the standard and/or increased dosage of the tablet formulation of lopinavir/r during pregnancy confers the same exposure to the drug as that observed in the same women after the end of pregnancy and in historic controls.
* To evaluate the transplacental passage of lopinavir/r based on the ratio between the serum concentration in maternal blood at the time of delivery and in cord blood of the two drug dosages (standard and increased) administered during pregnancy.
* To evaluate the tolerability of the two lopinavir/r dosages (standard and increased) during pregnancy.
* To describe the vertical transmission rate of HIV to the children of the pregnant women included in the study.


Eligibility Criteria:
Inclusion Criteria:

* Capacity to consent and wish to participate in the study, documented by signing the specific informed consent form (ICF) of the study.
* Age of 18 years or older.
* Pregnancy documented by urine or blood examination or ultrasound.
* Gestational age of 14 to 30 weeks calculated by ultrasound, obstetric examination or date of last menstruation, depending on what is considered to be more exact by the medical investigator.
* HIV infection documented by two serological tests using different methods or analysis of HIV viral load with a positive result.
* No use of antiretroviral drugs at the time of diagnosis of pregnancy (previous prophylaxis and treatment are allowed).
* Intention to continue the treatment of the study for at least 6 weeks after delivery.

Exclusion Criteria:

* History of hypersensitivity to lopinavir or ritonavir.
* Need for the concomitant use of contraindicated drugs in combination with lopinavir/ritonavir.
* Any condition that, in the opinion of the medical researchers, impairs the participation in and fulfillment of the procedures of the study.
Epilepsy Phenome/Genome Project

The purpose of this study is to collect detailed information about the characteristics and genetics of a large number of individuals with epilepsy.

Epilepsy is one of the most common neurological disorders and is a major public health concern. Approximately 30 percent of people with epilepsy have medically intractable epilepsy, and the medical and social consequences of the disorder are enormous. Treatments developed for epilepsy have largely been experimental rather than based on knowledge of basic mechanisms because the mechanisms are poorly understood.

The Epilepsy Phenome/Genome Project (EPGP) is a large-scale, international, multi-institutional, collaborative research project aimed at advancing the understanding of the genetic basis of the most common forms of epilepsy.

The overall goal of EPGP is to collect detailed, high quality phenotypic (i.e., characteristics of individuals, from the molecular level to the whole person) information on persons with epilepsy and to compare the phenotypic information with genomic information. EPGP will provide a resource that may lead to many discoveries related to the diagnosis and treatment of epilepsy, including the eventual development of new therapies based on a better understanding of causes of the disorder.

Eligibility Criteria:
Inclusion Criteria:

* Current age from 4 weeks to 60 years.
* Clear diagnosis of epilepsy, i.e., a lifetime history of two or more unprovoked seizures.
* Age at first unprovoked seizure younger than 40 years.
* High quality clinical and laboratory data (i.e., neuroimaging, EEG) must be available throughout the patient's history
* All patients with localization-related epilepsy (LRE) or idiopathic generalized epilepsy (IGE) must have a first-degree relative (parent, child, or sibling) with non-symptomatic (idiopathic or cryptogenic) epilepsy who is willing and available to participate.
* All patients with infantile spasms (IS), Lennox-Gastaut syndrome (LGS), or malformations of cortical development (MCD) must have both biological parents available and willing to participate.

Exclusion Criteria:

* Clinical and laboratory data do not allow a clear determination of whether the patient has epilepsy, or whether the diagnosis is LRE, IGE, IS, LGS, or MCD.
* Exclusively febrile seizures or other acute symptomatic seizures.
* Identified antecedent cause of epilepsy (i.e., a structural or metabolic insult to the CNS prior to the first unprovoked seizure, such as stroke, brain tumor, severe head trauma, etc., or a progressive neurodegenerative disorder).
* Recognized genetic syndrome (e.g., tuberous sclerosis, neurofibromatosis, Rett's or Angelman's syndromes) or chromosomal abnormality. (e.g., aneuploidies, unbalanced translocations, or chromosomal deletions and duplications detectable by conventional medical karyotyping).